Related Experiment Video
Updated: Dec 29, 2025
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
[Effect of CD56 Expression on Prognosis of AML Patients with AML/ETO Mutation]
1Department of Hematology，The First Affiliated Hospital of Xi'an Jiaotong University，Xi'an 710061，Shaanxi Province，China.
Objective:
To investigate the expression and prognostic significance of CD56 in the patients suffered from acute myeloid leukemia with AML/ETO mutation.
Methods:
The clinical data of 60 newly diagnosed AML patients with AML/ETO from January 2012 to December 2016 were analyzed retrospectively. The clinical characteristics and outcome between CD56+ and CD56- patients were compared.
Results:
There were significant differences in CR rate after one course chemotherapy, relapse rate within 1 year and gene mutations between the CD56 positive and negative patients (P＜0.05). The RFS and OS of CD56 positive patients were significantly lower than those of CD56 negative patients (P＜0.05).
Conclusion:
The expression of CD56 may be an important factor of poor prognosis in AML patients with AML/ETO.
More Related Videos
09:57Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells
Published on: January 29, 2019
07:38Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
